Subscribe to Search results

In an email chain discussing a "Telegraph" article about a post-mortem which was carried out on a man with haemophilia which found the vCJD prion in his spleen, it was held that an update should be urgently sent to people with bleeding disorders saying that "

Published on:

Professor Ironside reported to the HCDO the first positive result detecting the abnormal prion protein found in vCJD in a spleen sample from a patient included in the DH-funded prevalence study of vCJD infection in haemophilia.

Published on:

In Sir Ian Kennedy's statement he said that lack of scientific evidence that vCJD was transmitted by blood transfusion at the time was "crucial". If such evidence became available, recipients should be identified and notified, since at that point their futures would be wholly changed, and they were entitled to know that.

Published on:

In Dr Connor's written statement she remarked that, by 2014, the threshold was revised so that only patients who had received transfusions donated by an aggregate total of 300 or more donors were to be considered at risk for public health purposes.

Published on:

In Dr Connor's written statement, she said that by 2013, 11 patients who had received transfusions from more than 80 donors and were due to undergo surgery had been identified.

Published on:

The House of Commons Science and Technology Committee advised the Government take a more precautionary approach to both vCJD risk mitigation and blood safety more generally in order to safeguard against future infections.

Published on:

The National CJD Research & Surveillance Unit Annual Report stated that no new case of vCJD had been identified since 2016.

Published on:

Sir Robert Owen was invited to be chair of the Board of Trustees of the vCJD Trust.

Published on:

Studies had shown that 1 in 2,000 of the population had abnormal prion protein in their appendix and may be infected with vCJD.

Published on:

A Department of Health press release recommended the use of recombinant Factor 8 as the first choice of treatment for those with haemophilia.

Published on:

Professor Collinge told the Inquiry about the progression of vCJD, stating that about 1 in 5,000 people will develop it during their lifetime.

Published on:

Professor Ironside told the Inquiry that there had been 178 cases of vCJD in the UK identified as definite (supported by post-mortem) or probable (no post-mortem), though the latter category was virtually certain.

Published on:

In Dr Hewitt's oral evidence she referred to a case where a recipient developed vCJD, whose family had said that "If they had known that he had been at risk, his last few months would have been dealt with differently...they would have known what they were dealing with, or what they were likely to be dealing with."

Published on:

A man infected with Hepatitis C told the Inquiry that after being told he was "at-risk" for public health purposes he noticed a significant change in how he was treated by the medical profession, having been made to feel dirty and experiencing frustrating last minute changes of plan.

Published on:

A man was refused a liver biopsy as part of care for Hepatitis B and C.

Published on:

The "Expert Report to the Infected Blood Inquiry: Statistics" was produced, noting the statistic that no new case of vCJD has been identified since 2016.

Published on:

SEAC considered the results of two studies in "Nature" (in advance of their publication at the start of October 1997) and became convinced that the evidence of the link between BSE and vCJD had become "compelling".

Published on:

A review of three studies conducted between 1995 and 2014 of the prevalence with which abnormal prion proteins seen in samples of appendices removed at operation (hence "appendix studies", as they are known) found that 1 in 2,000 of the population had abnormal prion protein in their appendix.

Published on:

Mr AN told the Inquiry of having to insist upon procedures being carried out in the face of unwillingness from clinicians, and of then being made to wait around until the end of the patient list before being seen, and of having had procedures cancelled on the basis that there was no suitable equipment available.

Published on:

Morwenna Carrington told the Inquiry about reasons given by the Department of Health as to why a product was not adopted by the NHS in 2007 "as it did not achieve a category 1 rating from the RRP [Rapid Review Panel]. All manufacturers of products are required to have a category 1 rating to be suitable for the NHS. Other manufacturers developing similar pre-soaks also did not achieve a category 1 rating from the RRP and were not recommended for use in the NHS."

Published on: